A randomized, double-blind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysm
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2019
Price : $35 *
At a glance
- Drugs Canakinumab (Primary)
- Indications Abdominal aortic aneurysm
- Focus Therapeutic Use
- Sponsors Novartis
- 29 Jul 2016 This trial has been completed in Denmark (end date:2015-10-21) as per European Clinical Trials Database Record.
- 13 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 22 Sep 2014 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.